Johan Harmenberg M.D. Ph.D. Associate Prof.
Johan Harmenberg is Chief Medical Officer at Oncopeptides AB and medical advisor to Beactica since 2019. He has previously held roles at a number of life sciences companies including as CEO for Axelar AB and Akinion AB, Chief Medical Officer at Algeta AB, Vice President Development for Medivir AB and Global Medical Director for Pharmacia Upjohn. He is the author of over 100 publications for a range of scientific journals. Johan holds a PhD and MD from the Karolinska Institute in Stockholm, Sweden. He is also Associate Professor (Docent) at the same institution.
Helena Danielson Ph.D. Prof.
Helena Danielson is Professor of Biochemistry at Uppsala University since 2002 and co-founded Beactica in 2006. She is a specialist in enzyme-based drug discovery and has profound experience of the commercial drug discovery process through more than 25 years of collaborative research with industrial partners. Her longstanding work with biosensor technology and the Biacore technology for detailed studies of enzyme-inhibitor interactions has resulted in the development of new biosensor products of wide use in the discovery industry.
Jan Kihlberg Ph.D. Prof.
Jan Kihlberg is professor in Organic Chemistry at Uppsala University since 2013. During the previous ten years he held a position as Director of Medicinal Chemistry and then as Director of Competitive Intelligence and Business Foresight Analysis at AstraZeneca R&D Mölndal. He became Professor in Organic Chemistry at Umeå University in 1996 after having established his research group at Lund Institute of Technology in 1991. He holds a PhD in Organic Chemistry from Lund Institute of Technology. He has published 150 peer–reviewed publications, book chapters and patents.
Vendela Parrow Ph.D.
Vendela Parrow is currently Manager of the In Vitro and Systems Pharmacology Facility, SciLifeLab Drug Discovery and Development Platform. Dr Parrow was founder, CEO and later CSO of Akinion Pharmaceuticals AB during preclinical and clinical development of a novel kinase inhibitor for pharmaceutical treatment of AML. Dr Parrow also has experience from developmental biology and cytokine research. Before Akinion, Dr Parrow worked as project leader and scientific expert in a large number of projects at Pharmacia and Biovitrum.